Nature-CDK inhibitor CR8 acts as a molecular glue degradation agent to kill cancer cells
In the past few years, there has been a great interest in a class of promising drugs, which do not work by inhibiting the molecular target as most traditional drugs do, but use the cell recovery system to destroy the target. However, it is difficult to find and design such unusual compound drugs, which are collectively called the molecular glue degraders.
Now, a new molecular...